Probing the glycans accessibility in the nanoparticle biomolecular corona

Clemente, Eva; Moro, Marta Martínez; Trinh, Duong N; Soliman, Mahmoud G.; Spencer, Daniel I. R.; Gardner, Richard A.; Kotsias, Maximilianos; Iglesias, Ana Sánchez; Moya, Sergio; Monopoli, Marco P.

doi:10.1016/j.jcis.2021.11.140

Cited by 20 publications

(20 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To study the glycan profile of the silica corona, we modified a standard protocol using PNGaseF enzyme which cleaves the linkage between the core N-acetylglucosamine (GlcNAc) and the asparagine residue on proteins, releasing all N-glycans except those containing a fucose α1-3 linked to the reducing terminal GlcNAc found in nonhuman species. , The released glycans were labeled with a fluorophore before being analyzed by HILIC chromatography coupled with a fluorescence detector and electrospray ionization MS (HILIC-FD-ESI-MS). Using a 70 min HPLC gradient alongside ESI-MS allowed the identification of 56 peaks, 46 of them were assigned with the glycan structures (Figure and Table S2).…”

Section: Resultsmentioning

confidence: 99%

Nanoparticle Biomolecular Corona-Based Enrichment of Plasma Glycoproteins for N-Glycan Profiling and Application in Biomarker Discovery

et al. 2022

Self Cite

View full text Add to dashboard Cite

Biomolecular corona formation has emerged as a recurring and important phenomenon in nanomedicine that has been investigated for potential applications in disease diagnosis. In this study, we have combined the “personalized protein corona” with the N-glycosylation profiling that has recently gained considerable interest in human plasma biomarker discovery as a powerful early warning diagnostic and patient stratification tool. We envisioned that the protein corona formation could be exploited as an enrichment step that is critically important in both proteomic and proteoglycomic workflows. By using silica nanoparticles, plasma fibrinogen was enriched to a level in which its proteomic and glycomic “fingerprints” could be traced with confidence. Despite being a more simplified glycan profile compared to full plasma, the corona glycan profile revealed a fibrinogen-derived glycan peak that was found to potentially distinguish lung cancer patients from controls in a pilot study.

show abstract

Section: Resultsmentioning

confidence: 99%

Nanoparticle Biomolecular Corona-Based Enrichment of Plasma Glycoproteins for N-Glycan Profiling and Application in Biomarker Discovery

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…[ 75 ] The formation of the biomolecular corona is not necessarily associated with the hindering of the interaction of glycosylated nanoparticles with glycan‐binding biomolecules. [ 76 ]…”

Section: Resultsmentioning

confidence: 99%

“…[75] The formation of the biomolecular corona is not necessarily associated with the hindering of the interaction of glycosylated nanoparticles with glycan-binding biomolecules. [76] To perform biodistribution studies, mucosomes were loaded with a fluorescent dye suitable for in vivo imaging tests. It is essential that the absorption and emission wavelength of the dye fall in a spectral region in which the interference with the biological matrix is minimal.…”

Section: Enzymatic Stability Interaction With Serum and In Vivo Biodi...mentioning

confidence: 99%

Mucosomes: Intrinsically Mucoadhesive Glycosylated Mucin Nanoparticles as Multi‐Drug Delivery Platform

Butnarasu

Petrini

Bracotti

et al. 2022

Adv Healthcare Materials

View full text Add to dashboard Cite

Mucus is a complex barrier for pharmacological treatments and overcoming it is one of the major challenges faced during transmucosal drug delivery. To tackle this issue, a novel class of glycosylated nanoparticles, named "mucosomes," which are based on the most important protein constituting mucus, the mucin, is introduced. Mucosomes are designed to improve drug absorption and residence time on the mucosal tissues. Mucosomes are produced (150-300 nm), functionalized with glycans, and loaded with the desired drug in a single one-pot synthetic process and, with this method, a wide range of small and macro molecules can be loaded with different physicochemical properties. Various in vitro models are used to test the mucoadhesive properties of mucosomes. The presence of functional glycans is indicated by the interaction with lectins. Mucosomes are proven to be storable at 4 °C after lyophilization, and administration through a nasal spray does not modify the morphology of the mucosomes. In vitro and in vivo tests indicate mucosomes do not induce adverse effects under the investigated conditions. This study proposes mucosomes as a ground-breaking nanosystem that can be applied in several pathological contexts, especially in mucus-related disorders.

show abstract

“…In this regard, it has been well established that NPs in contact with the biological environment adsorb biomolecules, such as lipids or proteins, forming the so-called bio-corona. This biomolecular coating dictates the biological “identity” of the NPs, affecting their activity, biodistribution and clearance ( Cedervall et al, 2007 ; Nel et al, 2009 ; Monopoli et al, 2011 ; Monopoli et al, 2012 ; Clemente et al, 2022 ). When these proteins are opsonins, the NPs are recognized by the MPS, and they are eliminated.…”

Section: Pegylation For Biomedical Applicationsmentioning

confidence: 99%

Understanding the Role and Impact of Poly (Ethylene Glycol) (PEG) on Nanoparticle Formulation: Implications for COVID-19 Vaccines

Padín-González

Lancaster

Bottini

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Poly (ethylene glycol) (PEG) is a widely used polymer in a variety of consumer products and in medicine. PEGylation refers to the conjugation of PEG to drugs or nanoparticles to increase circulation time and reduce unwanted host responses. PEG is viewed as being well-tolerated, but previous studies have identified anti-PEG antibodies and so-called pseudoallergic reactions in certain individuals. The increased use of nanoparticles as contrast agents or in drug delivery, along with the introduction of mRNA vaccines encapsulated in PEGylated lipid nanoparticles has brought this issue to the fore. Thus, while these vaccines have proven to be remarkably effective, rare cases of anaphylaxis have been reported, and this has been tentatively ascribed to the PEGylated carriers, which may trigger complement activation in susceptible individuals. Here, we provide a general overview of the use of PEGylated nanoparticles for pharmaceutical applications, and we discuss the activation of the complement cascade that might be caused by PEGylated nanomedicines for a better understanding of these immunological adverse reactions.

show abstract

Probing the glycans accessibility in the nanoparticle biomolecular corona

Cited by 20 publications

References 46 publications

Nanoparticle Biomolecular Corona-Based Enrichment of Plasma Glycoproteins for N-Glycan Profiling and Application in Biomarker Discovery

Nanoparticle Biomolecular Corona-Based Enrichment of Plasma Glycoproteins for N-Glycan Profiling and Application in Biomarker Discovery

Mucosomes: Intrinsically Mucoadhesive Glycosylated Mucin Nanoparticles as Multi‐Drug Delivery Platform

Understanding the Role and Impact of Poly (Ethylene Glycol) (PEG) on Nanoparticle Formulation: Implications for COVID-19 Vaccines

Contact Info

Product

Resources

About